tiprankstipranks
Advertisement
Advertisement
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
PremiumRatingsEarly Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
2M ago
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
Premium
Ratings
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
2M ago
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
Premium
Ratings
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
2M ago
Aktis Oncology initiated with an Outperform at William Blair
PremiumThe FlyAktis Oncology initiated with an Outperform at William Blair
3M ago
Aktis Oncology appoints Gormley as independent director of Board of Directors
Premium
The Fly
Aktis Oncology appoints Gormley as independent director of Board of Directors
3M ago
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
Premium
Ratings
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
4M ago
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
PremiumCompany AnnouncementsAktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
5M ago
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
Premium
Ratings
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
5M ago
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
Premium
The Fly
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100